ABSTRACT

The immune system is not fully developed in human neonates and infants; breastfeeding is important in this stage as the bioactive components of human breast milk are known to have anti-microbial, anti-inflammatory, and immunomodulatory effects, and can therefore contribute to an infant's immunity against allergies, asthma, autoimmune diseases, and inflammatory bowel disease. Herein, the positive effect on the immune system by human colostrum and milk are reviewed.

Keywords: Human milk; Immune system; Breastfeeding

INTRODUCTION

The mortality rate of breastfed babies at all ages of infancy was reported to be lower even in studies published as early as 1922 [1]. According to a 1968 study by Scrimshaw et al. [2], the mortality rate of artificially fed infants was seven times that of breastfed babies. The high positive influence of breastfeeding on the life span and mortality rate is attributed to the immunomodulatory effects of breast milk.

In a systematic review published in 2003, Jones et al. [3] predicted that exclusive breastfeeding through the first six months could prevent 13% of childhood deaths in children younger than 5 years of age. Notably, the maximization of the immunological effects of breastfeeding is dependent on the dose-response relationship and varies according to breastfeeding exclusivity and duration.

The immune system of a newborn baby is immature at birth and develops more rapidly during the first two years of life. Specifically, the immature neonatal immune system is deficient in its ability to produce B lymphocytes and immunoglobulins and is limited in its systemic cell-mediated immune response. Neutrophil activity is delayed, which renders infants susceptible to bacterial infections. Additionally, several immune components are produced in low or limited quantities, including complements from the complement system/cascade, interferon-gamma (IFNγ), secretory immunoglobulin A (sIgA), interleukins (ILs), tumor necrosis factors (TNFs), lactoferrin, and lysozyme [4]. Thus, the various bioactive and immunomodulatory factors that are present in human milk can complement the development of the mucosal and systemic immune systems of neonates [5,6].
BIOACTIVE FACTORS IN HUMAN MILK

The important components of human milk can be categorized into three main groups: bioactive factors, proteins, and fats. Bioactive factors include nutritional components (macronutrients, lactoferrin, transferrin, vitamin B_{12}-binding protein), hormones (erythropoietin, prolactin, insulin, gonadotropins, ovarian steroids, thyroid-releasing hormone, thyroid-stimulating hormone, etc.), growth factors (epithelial growth factor, insulin-like growth factor, etc.), neuropeptides (neurotensin, somatostatin, bombesin, etc.), cytokines (TNFα, IL-6, etc.), prebiotics, and nucleotides [7,8].

Milk proteins are essentially divided into whey components and casein; the most abundant proteins are casein, lactoferrin, alpha-lactalbumin, sIgA, and lysozyme. The protein content is higher in the milk from mothers of preterm babies than in the milk from the mothers of term babies [9]. Although milk protein concentration does not change according to the quantity of protein consumed by the mother, it increases with increasing body weight for height of the individual and decreases in mothers with enhanced breast milk production [10].

Human hindmilk contains a 2–3 times higher fat concentration than foremilk, with palmitic and oleic acids making up the major fat types [11]. Milk fat globules (MFGs), which are composed of glycoproteins and lipids, are the second most abundant fat in human milk. These membrane glycoproteins act as antibacterial and antiviral ligands, preventing pathogens from attaching to the intestinal mucosa, thereby protecting the infant from infection [12]. MFGs also contain mucins (MUC1 and MUC4) [13]. MUC1 blocks human immunodeficiency virus (HIV) and rotavirus [14], and both MUC1 and MUC4 block *Salmonella* species and Norwalk virus.

Bioactive factors in human milk originate from diverse sources. Some are produced by the mammary epithelial cells, some by the cells within the milk [15], while others are present in the maternal serum and are transported across the mammary epithelium. Furthermore, the secretion of MFGs into milk by the mammary epithelial cells carry a variety of membrane-bound proteins and lipids [16].

IMMUNOLOGICAL FACTORS

Human milk produced during the early lactation period delivers approximately 10^8 maternal leukocytes to infants per day. The quantity of these cells differs among mothers and has been shown to be correlated with a later diagnosis of cow's milk intolerance in breastfed infants [17].

Approximately 80% of leukocytes in early human breast milk are macrophages that migrate from the bloodstream into the milk through the mammary epithelium. These mononuclear leukocytes have the ability to act as potent breast milk macrophages through phagocytosis of human milk components and their differentiation into dendritic cells that stimulate T-cell activity and can therefore provide powerful protection against pathogens [18]. However, in women that test positive for HIV-1 or human T-cell lymphotropic virus type 1, the activity of these leukocytes can increase the risk of mother-to-infant viral transmission.

Cytokines in human milk can cross the intestinal barrier and influence the immune system activity in newborns. For example, transforming growth factor-beta (TGF-β) regulates...
inflammation and wound repair and prevents allergic diseases [19], whereas granulocyte colony-stimulating factor (G-CSF) beneficially affects intestinal development and the treatment of severe infections [20]. G-CSF is not well absorbed at the intestinal surface and instead increases the villus area, crypt depth, and proliferating cell nuclear antigen index; that is, it acts as a topical intestinal growth factor in infants that have ingested breast milk [21]. Other human milk cytokines (e.g., IL-10 and IL-7) can also cross the intestinal wall, with IL-7, in particular, affecting thymic development [22].

The proinflammatory cytokines in human milk are TNFα, IL-6, IL-8, and IFNγ. Although their quantities in breast milk are very small and decrease during lactation [23], they can still recruit neutrophils and enhance intestinal mucosal development. IL-8 may protect against TNFα-mediated tissue damage [24,25]. Although higher levels of IL-6 and IL-8 were found in patients with mastitis, the elevation in levels were noted only in the affected mammary lobes [26,27]. IFNγ, which enhances the Th1/inflammatory response and suppresses the Th2/allergic response [28], was found to be lower in thecolostrum of mothers who suffered from allergies, and the levels of the Th2 cytokines IL-4 and IL-13 in those samples were higher than those in the cells of thecolostrum of mothers with no allergies [29].

Infants are also born with an immature acquired/adaptive immune system, and therefore have to rely on maternal antibodies to fight pathogens [30]. sIgA, the predominant antibody in human milk, forms a complex with antigens, whereupon they are taken up by intestinal dendritic cells that recognize the foreign antigen [31]. Although the levels of IgM and IgG are low in human colostrum, IgG later becomes more abundant in breast milk [32].

**HUMAN MILK OLIGOSACCHARIDES: PREVENTION OF ALLERGIC DISEASE AND COMPOSITION OF BENEFICIAL MICROBIOTA**

A large portion of human milk is made up of human milk oligosaccharides (HMOs) that have no actual nutritional value [33] but can act as prebiotics to enhance the growth of probiotic organisms in the infant gut. The conjugates formed from the HMOs and the proteins of probiotic organisms serve as soluble “decoy” receptors for pathogens on the infant’s intestinal surface. HMO structures differ among mothers owing to genetic differences [34]. Because human milk also contains microbial organisms, which can change according to the lactation course and maternal characteristics, HMOs may further influence the bacterial composition of breast milk, and subsequently the intestinal microbiome of the breastfed infant [35].

*Enterobacteriaceae* and *Staphylococci* first colonize in the neonatal intestines [36], and *Bifidobacteria* and lactic acid bacteria colonize in the intestines later [37]. HMOs promote the colonization and growth of beneficial intestinal bacteria, such as *Bifidobacterium* (B) and *Lactobacillus* (L) [38,39]. A study reported the effects of HMOs when gut colonization in breastfed and formula-fed infants was compared [40].

Both *B. longum* and *B. bifidum* are the major intestinal bacteria found in breastfed infants and metabolize HMOs. In contrast, *B. adolescentis* is usually observed in the adult intestine and is less effective in metabolizing HMOs [41].
In contrast to *Bifidobacterium* spp., *Bacteroides* spp. are not specifically adapted to metabolize HMOs [42]. Suitable substrate for commensal gut bacteria leads to growth advantage for these bacteria, increasing proper colonization in the intestine and reducing colonization by pathogenic bacteria [43,44].

Certain pathogenic species, including *Clostridium difficile*, *Enterococcus faecalis*, and *Escherichia coli*, do not use HMOs as their carbohydrate substrate source for growth [45]. However, HMOs actively bind to several pathogenic bacteria, thereby preventing adhesion to the intestinal epithelium, which is the first step of infection [46]. Although the infant formula is supplemented with prebiotic oligosaccharide substances, these added oligosaccharides do not contain effective chemical substances of terminal fucose or sialic acid residues, thus missing the biological function of HMOs [47].

HMOs also enhance mucus production and promote epithelial tight junction integrity, thereby supporting epithelial barrier function and directly affecting immune cell activity in the gastrointestinal tract of neonates. Additionally, HMOs modulate the response of dendritic cells, which have protective effects on the development of mucosal immunity. These HMO-related mechanisms may work together to prevent allergic diseases in breastfed infants [48]. In various studies performed in human infants, HMOs also showed positive protective effects against infections, such as those caused by *Campylobacter*. However, there is a lack of studies on infant health [49].

Additionally, a link between human milk and allergic outcome in later life has been published in 1936 by Grulee and Sanford [50]. A number of studies have reported this association [51-56]. Newborns may develop allergic diseases because their immune system is dominated by T helper 2 cell (Th2) responsiveness during the neonatal period [57]. Shifting the immune response towards a more T helper 1 (Th1) of the prone and regulatory type favors the development of immune protection and balanced immunologic responses [58]. Epithelial barrier and mucosal homeostasis are important in the prevention of allergic sensitization and have evoked interest. HMOs could support this function by enhancing proper epithelial maturation and helping to compose microbial colonization [59-61].

**MICRO RNAs IN HUMAN MILK**

Micro RNAs (miRNAs) modulate the activity of specific mRNA targets and are known to play important roles in both physiological and pathological processes in mammals. They are also involved in immunologic reactions [62]. Serum miRNAs can be used as potential biomarkers for various cancers and other diseases. miRNAs in human milk were first profiled in 2010 by Kosaka et al. [63], who also reported high expression levels of immune-related miRNAs in the first six months of lactation. Until this study was reported, the physiological roles of body fluid miRNAs were undetermined.

Almost 1,400 different mature miRNAs have been documented in human breast milk, which vary in colostrum, mature milk, milk cells, milk lipids, and milk exosomes [64]. After being transported to the intestine through lactation, miRNAs remain intact in the degradative processes of digestion and are absorbed by epithelial cells. Then, miRNAs reach various tissues and organs, where they perform immunological functions and developmental programming in the infant immune system [65].
STEM CELLS IN HUMAN MILK

The presence of stem cells in the mammary gland was first postulated because the mammary epithelia expand and regress throughout adult life [66]. Mammary stem cells (MaSCs) are present in a quiescent state and in few numbers in the resting breast, but become activated during pregnancy and lactation, as if programmed for proliferation, differentiation, and apoptosis [67]. During the development of invasive breast carcinoma, MaSCs implicate both mesodermal and endodermal organs [68,69]. This indicates that the mammary gland harbor stem cells with self-renewal capabilities, both in normal and aberrant conditions. The molecular determinants and regulators of MaSCs are poorly understood. Human lactating breast tissues contain a greater number of activated MaSCs [70]. Hassiotou et al. [71], reported that human milk contains stem cells (human breast stem cells, hBSCs) that contain many genes present in human embryonic stem cells (hESCs), which contain factors for core self-renewal circuitry of hESCs. They also reported that hBSCs differentiated into cell lineages from all three germ layers in vitro, suggesting the potential of hBSCs for use in research on adult stem cell plasticity and breast cancer.

EFFECTS OF PASTEURIZATION AND STORAGE ON THE COMPONENTS OF HUMAN MILK

Most mothers store their expressed milk in a refrigerator or freezer for long periods, during which the immunological components, micronutrients, and diverse trophic factors as well as the dynamic nature of the milk composition may be altered. These changes were also noted in pasteurized cow and human milk, in which the levels of sIgA, lysozyme, cytokines, TGF-β, lipases, and adiponectin were reduced [72,73]. Specifically, the levels of IFNγ, TNFα, IL-1β, IL-10, and hepatocyte growth factor were found to be significantly reduced following Holder pasteurization (62.5°C for 30 minutes) of donated human breast milk [73]. Freeze–thaw cycles also cause some damage to the lysozyme, IgA, and lactoferrin components, as was frequently noted in some donor milk for preterm babies [74].

CONCLUSION

The ingredients in human milk that contribute to its immunomodulatory effects are extremely diverse, and each bear characteristics that need to be individually studied. Such knowledge can help sufficiently educate breastfeeding mothers and thus ensure good health of their babies.

REFERENCES

1. Woodbury RM. The relation between breast and artificial feeding and infant mortality. Am J Epidemiol 1922;2:668-87.
2. Scrimshaw NS, Taylor CE, Gordon JE. Interactions of nutrition and infection. Monogr Ser World Health Organ 1968;57:3-329.
3. Jones G, Stekete RW, Black RE, Bhutta ZA, Morris SS; Bellagio Child Survival Study Group. How many child deaths can we prevent this year? Lancet 2003;362:65-71.
4. Lawrence RM, Pane CA. Human breast milk: current concepts of immunology and infectious diseases. Curr Probl Pediatr Adolesc Health Care 2007;37:7-36.

5. Goldman AS, Chheda S, Garofalo R. Evolution of immunologic functions of the mammary gland and the postnatal development of immunity. Pediatr Res 1998;43:155-62.

6. Hansson LA, Silfverdal SA, Korotkova M, Erling V, Strömbeck L, Olcén P, et al. Immune system modulation by human milk. Adv Exp Med Biol 2002;503:99-106.

7. Hamosh M. Bioactive factors in human milk. Pediatr Clin North Am 2001;48:69-86.

8. Ballard O, Morrow AL. Human milk composition: nutrients and bioactive factors. Pediatr Clin North Am 2013;60:49-74.

9. Bauer J, Gerss J. Longitudinal analysis of macronutrients and minerals in human milk produced by mothers of preterm infants. Clin Nutr 2011;30:215-20.

10. Nommsen LA, Lovelady CA, Heinig MJ, Lönnerdal B, Dewey KG. Determinants of energy, protein, lipid, and lactose concentrations in human milk during the first 12 mo of lactation: the DARLING Study. Am J Clin Nutr 1991;53:457-65.

11. Saa T, Koko K, Koivist M. Macronutrient and energy contents of human milk fractions during the first six months of lactation. Acta Paediatr 2005;94:8176-81.

12. Hamosh M, Peterson JA, Henderson TR, Scallan CD, Kiwan R, Ceriani RL, et al. Protective function of human milk: the milk fat globule. Semin Perinatol 1999;23:242-9.

13. Hettinga K, van Valenberg H, de Vries S, Boeren S, van Hooijdonk T, van Arendonk J, et al. The host defense proteome of human and bovine milk. PLoS One 2011;6:e19433.

14. Saeland E, de Jong MA, Nabatov AA, Kalay H, Geijtenbeek TB, van Kooyk Y. MUC1 in human milk blocks transmission of human immunodeficiency virus from dendritic cells to T cells. Mol Immunol 2009;46:2309-16.

15. Garofalo R. Cytokines in human milk. J Pediatr 2010;156(2 Suppl):S36-40.

16. Cavaletto M, Giuffrida MG, Conti A. The proteomic approach to analysis of human milk fat globule membrane. Clin Chim Acta 2004;347:41-8.

17. Järvinen KM, Suomalainen H. Leucocytes in human milk and lymphocyte subsets in cow’s milk-allergic infants. Pediatr Allergy Immunol 2002;13:243-54.

18. Ichikawa M, Sugita M, Takahashi M, Satomi M, Takeshita T, Araki T, et al. Breast milk macrophages spontaneously produce granulocyte-macrophage colony-stimulating factor and differentiate into dendritic cells in the presence of exogenous interleukin-4 alone. Immunology 2003;108:189-95.

19. Penttila IA. Milk-derived transforming growth factor-beta and the infant immune response. J Pediatr 2010;156(2 Suppl):S21-5.

20. Gilmore WS, McKelvey-Martin VJ, Rutherford S, Strain JJ, Loane P, Kell M, et al. Human milk contains granulocyte colony stimulating factor. Eur J Clin Nutr 1994;48:222-4.

21. Gersting JA, Christensen RD, Calhoun DA. Effects of enterally administering granulocyte colony-stimulating factor to suckling mice. Pediatr Res 2004;55:802-6.

22. Aspinall R, Prentice AM, Ngom PT. Interleukin 7 from maternal milk crosses the intestinal barrier and modulates T-cell development in offspring. PLoS One 2011;6:e20812.
23. Castellote C, Casillas R, Ramírez-Santana C, Pérez-Cano FJ, Castell M, Moretones MG, et al. Premature delivery influences the immunological composition of colostrum and transitional and mature human milk. J Nutr 2011;141:1181-7.

24. Maheshwari A, Christensen RD, Calhoun DA. ELR+ CXC chemokines in human milk. Cytokine 2003;24:94-102.

25. Maheshwari A, Lu W, Lacson A, Barleycorn AA, Nolan S, Christensen RD, et al. Effects of interleukin-8 on the developing human intestine. Cytokine 2002;20:256-67.

26. Mizuno K, Hatsuno M, Aikawa K, Takeichi H, Himi T, Kaneko A, et al. Mastitis is associated with IL-6 levels and milk fat globule size in breast milk. J Hum Lact 2012;28:529-34.

27. Hunt KM, Williams JE, Shafii B, Hunt MK, Behro R, Ting R, et al. Mastitis is associated with increased free fatty acids, somatic cell count, and interleukin-8 concentrations in human milk. Breastfeed Med 2013;8:105-10.

28. Agarwal S, Karmaus W, Davis S, Gangur V. Immune markers in breast milk and fetal and maternal body fluids: a systematic review of perinatal concentrations. J Hum Lact 2011;27:171-86.

29. Hrdý J, Novotná O, Kocourková I, Prokesová L. Cytokine expression in the colostral cells of healthy and allergic mothers. Folia Microbiol (Praha) 2012;57:215-9.

30. Brandzaeg P. The mucosal immune system and its integration with the mammary glands. J Pediatr 2010;156(2 Suppl):S8-15.

31. Kadaoui KA, Corthésy B. Secretory IgA mediates bacterial translocation to dendritic cells in mouse Peyer's patches with restriction to mucosal compartment. J Immunol 2007;179:7751-7.

32. Gao X, McMahon RJ, Woo JG, Davidson BS, Morrow AL, Zhang Q. Temporal changes in milk proteomes reveal developing milk functions. J Proteome Res 2012;11:3897-907.

33. Gabrielli O, Zampini L, Galeazzi T, Padella L, Santoro L, Peila C, et al. Preterm milk oligosaccharides during the first month of lactation. Pediatrics 2011;128:e1520-31.

34. Newburg DS, Ruiz-Palacios GM, Morrow AL. Human milk glycans protect infants against enteric pathogens. Annu Rev Nutr 2005;25:37-58.

35. Hunt KM, Foster JA, Forney LJ, Schütte UM, Beck DL, Abdo Z, et al. Characterization of the diversity and temporal stability of bacterial communities in human milk. PLoS One 2011;6:e21313.

36. Matsuki T, Yahagi K, Mori H, Matsumoto H, Hara T, Tajima S, et al. A key genetic factor for fucosyllactose utilization affects infant gut microbiota development. Nat Commun 2016;7:11939.

37. Yu ZT, Chen C, Newburg DS. Utilization of major fucosylated and siaIyated human milk oligosaccharides by isolated human gut microbes. Glycobiology 2013;23:1281-92.

38. Underwood MA, Davis JCC, Kalanetra KM, Gehlot S, Patole S, Tancredi DJ, et al. Digestion of human milk oligosaccharides by Bifidobacterium breve in the premature infant. J Pediatr Gastroenterol Nutr 2017;65:449-55.

39. Thongaram T, Hoeflinger JL, Chow J, Miller MJ. Human milk oligosaccharide consumption by probiotic and human-associated bifidobacteria and lactobacilli. J Dairy Sci 2017;100:7825-33.

40. Wang M, Li M, Wu S, Lebrilla CB, Chapkin RS, Ivanov I, et al. Fecal microbiota composition of breastfed infants is correlated with human milk oligosaccharides consumed. J Pediatr Gastroenterol Nutr 2015;60:825-33.
41. LoCascio RG, Ninonuevo MR, Freeman SL, Sela DA, Grimm R, Lebrilla CB, et al. Glycoprofiling of bifidobacterial consumption of human milk oligosaccharides demonstrates strain specific, preferential consumption of small chain glycans secreted in early human lactation. J Agric Food Chem 2007;55:8914-9.

42. Marcobal A, Sonnenburg JL. Human milk oligosaccharide consumption by intestinal microbiota. Clin Microbiol Infect 2012;18 Suppl 4:12-5.

43. Desai MS, Seekatz AM, Koropatkin NM, Kamada N, Hickey CA, Wolter M, et al. A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility. Cell 2016;167:1339-53.e21.

44. Makki K, Deehan EC, Walter J, Bäckhed F. The impact of dietary fiber on gut microbiota in host health and disease. Cell Host Microbe 2018;23:705-45.

45. Marcobal A, Barboza M, Froehlich JW, Block DE, German JB, Lebrilla CB, et al. Consumption of human milk oligosaccharides by gut-related microbes. J Agric Food Chem 2010;58:5334-40.

46. Coppa GV, Zampini L, Galeazzi T, Facinelli B, Ferrante L, Capretti R, et al. Human milk oligosaccharides inhibit the adhesion to Caco-2 cells of diarrheal pathogens: Escherichia coli, Vibrio cholerae, and Salmonella fyris. Pediatr Res 2006;59:377-82.

47. Weiss GA, Hennet T. The role of milk sialyllactose in intestinal bacterial colonization. Adv Nutr 2012;3:483S-8S.

48. Ayechu-Muruzabal V, van Stigt AH, Mank M, Willemsen LEM, Stahl B, Garssen J, et al. Diversity of human milk oligosaccharides and effects on early life immune development. Front Pediatr 2018;6:239.

49. Kim SY, Yi DY. Components of human breast milk: from macronutrient to microbiome and microRNA. Clin Exp Pediatr 2020;63:301-9.

50. Grulee CG, Sanford HN. The influence of breast and artificial feeding on infantile eczema. J Pediatr 1936;9:223-5.

51. Nwaru BI, Craig LC, Allan K, Prabhu N, Turner SW, McNeill G, et al. Breastfeeding and introduction of complementary foods during infancy in relation to the risk of asthma and atopic diseases up to 10 years. Clin Exp Allergy 2013;43:1263-73.

52. Nwaru BI, Takkinen HM, Niemelä O, Kaila M, Erkkola M, Ahonen S, et al. Timing of infant feeding in relation to childhood asthma and allergic diseases. J Allergy Clin Immunol 2013;131:78-86.

53. Lowe AJ, Thien FC, Stoney RM, Bennett CM, Hosking CS, Hill DJ, et al. Associations between fatty acids in colostrum and breast milk and risk of allergic disease. Clin Exp Allergy 2008;38:1745-51.

54. Wijga AH, van Houwelingen AC, Kerkhof M, Tabak C, de Jongste JC, Gerritsen J, et al. Breast milk fatty acids and allergic disease in preschool children: the Prevention and Incidence of Asthma and Mite Allergy birth cohort study. J Allergy Clin Immunol 2006;117:440-7.

55. Lee MT, Wu CC, Ou CY, Chang JC, Liu CA, Wang CL, et al. A prospective birth cohort study of different risk factors for development of allergic diseases in offspring of non-atopic parents. Oncotarget 2017;8:10858-70.

56. Elbert NJ, van Meel ER, den Dekker HT, de Jong NW, Nijsten TEC, Jaddoe VWV, et al. Duration and exclusiveness of breastfeeding and risk of childhood atopic diseases. Allergy 2017;72:1936-43.

57. Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev 2003;8:223-46.

58. Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans from infancy to old age. Proc Biol Sci 2015;282:20143085.
59. Holscher HD, Davis SR, Tappenden KA. Human milk oligosaccharides influence maturation of human intestinal Caco-2Bbe and HT-29 cell lines. J Nutr 2014;144:586-91.
PUBMED | CROSSREF

60. Holscher HD, Bode L, Tappenden KA. Human milk oligosaccharides influence intestinal epithelial cell maturation in vitro. J Pediatr Gastroenterol Nutr 2017;64:296-301.
PUBMED | CROSSREF

61. Bäckhed F, Roswall J, Peng Y, Feng Q, Jia H, Kovatcheva-Datchary P, et al. Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe 2015;17:690-703.
PUBMED | CROSSREF

62. Tili E, Michaille JJ, Calin GA. Expression and function of micro-RNAs in immune cells during normal or disease state. Int J Med Sci 2008;5:73-9.
PUBMED | CROSSREF

63. Kosaka N, Izumi H, Sekine K, Ochiya T. microRNA as a new immune-regulatory agent in breast milk. Silence 2010;1:7.
PUBMED | CROSSREF

64. Alsaweed M, Hartmann PE, Geddes DT, Kakulas F. MicroRNAs in breastmilk and the lactating breast: potential immunoprotectors and developmental regulators for the infant and the mother. Int J Environ Res Public Health 2015;12:13981-4020.
PUBMED | CROSSREF

65. Melnik BC, Schmitz G. MicroRNAs: milk’s epigenetic regulators. Best Pract Res Clin Endocrinol Metab 2017;31:427-42.
PUBMED | CROSSREF

66. Taylor-Papadimitriou J, Shearer M, Stoker MG. Growth requirements of human mammary epithelial cells in culture. Int J Cancer 1977;20:903-8.
PUBMED | CROSSREF

67. Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL, et al. Progesterone induces adult mammary stem cell expansion. Nature 2010;465:803-7.
PUBMED | CROSSREF

68. Lu X, Wang Q, Hu G, Van Poznak C, Fleisher M, Reiss M, et al. ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev 2009;23:1882-94.
PUBMED | CROSSREF

69. Oskarsson T, Acharya S, Zhang XH, Vanharanta S, Tavazoie SF, Morris PG, et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med 2011;17:867-74.
PUBMED | CROSSREF

70. Tiede B, Kang Y. From milk to malignancy: the role of mammary stem cells in development, pregnancy and breast cancer. Cell Res 2011;21:245-57.
PUBMED | CROSSREF

71. Hassiotou F, Beltran A, Chetwynd E, Stuebe AM, Twigger AJ, Metzger P, et al. Breastmilk is a novel source of stem cells with multilineage differentiation potential. Stem Cells 2012;30:2164-74.
PUBMED | CROSSREF

72. Peroni DG, Piacentini GL, Bodini A, Pigozzi R, Boner AL. Transforming growth factor-beta is elevated in unpasteurized cow’s milk. Pediatr Allergy Immunol 2009;20:42-4.
PUBMED | CROSSREF

73. Ewaschuk JB, Unger S, O’Connor DL, Stone D, Harvey S, Clandinin MT, et al. Effect of pasteurization on selected immune components of donated human breast milk. J Perinatol 2011;31:593-8.
PUBMED | CROSSREF

74. Akinbi H, Meinzen-Derr J, Auer C, Ma Y, Pullum D, Kusano R, et al. Alterations in the host defense properties of human milk following prolonged storage or pasteurization. J Pediatr Gastroenterol Nutr 2010;51:347-52.
PUBMED | CROSSREF